Provided herein are in vitro methods of assaying an in vivo level of high molecular weight (HMW) species of a therapeutic protein. In exemplary embodiments, the method comprises (a) incubating a mixture comprising (i) a sample comprising the therapeutic protein and (ii) serum, or a depleted fraction thereof; and (b) assaying the level of HMW species of the therapeutic protein present in the mixture at one or more time points after step (a). Also methods of determining the in vivo reversibility of HMW species of a therapeutic protein are provided herein. In exemplary instances, the method comprises (A) assaying the in vivo level of high molecular weight (HMW) species of a therapeutic protein according to a presently disclosed in vitro method, and (B) comparing the level(s) of HMW species present in the mixture to the level of HMW species present in the sample prior to the incubating step.

The present invention relates to a method for determining the distinctive nutritional requirements of a patient with specific nutritional needs and providing a composition meeting the distinctive nutritional requirements of said patient.

The present invention generally pertains to methods of determining the amino acid sequence of a protein. In particular, the present invention pertains to the use of position-selective dimethylation and liquid chromatography-mass spectrometry to enhance the signal of N-terminal peptides and shift the signal of N-terminal peptides and corresponding b ions, thus facilitating a determination of the sequence of N-terminal peptides.

The invention relates to an in silico screening method to identify candidate excipients for reducing aggregation of a protein in a formulation. The method combines computational molecular modeling and molecular dynamics simulations to identify sites on a protein where non-specific self-interaction and interaction of different test excipients may occur, determine the relative binding energies of such interactions, and select one or more test excipients that meet specified interaction criteria for use as candidate excipients in empirical screening studies.

The present invention relates to an apparatus for diagnosing solid cancers comprising lung cancer, pancreatic cancer, bile duct cancer, colorectal cancer, breast cancer, gastric cancer, brain tumors, kidney cancer, liver cancer, and cervical cancer. More specifically, the apparatus comprises: a concentration measurement unit for measuring the concentration of each of acyl-carnitine (AC), nudifloramide (2PY), and lysophosphatidylcholine (LPC) from a biological sample; a pre-processing unit for pre-processing the measured concentrations; and a diagnosis unit for determining the diagnosis information of cancer through linear discriminant analysis using the pre-processed concentrations.

The disclosure is directed to methods for preventing or treating cardiovascular disease and kidney dysfunction in certain patient populations which involve determining the level of soluble urokinase plasminogen activator receptor (suPAR) protein in a sample obtained from a subject, and performing various therapeutic interventions based on the suPAR level in the sample.

The present invention concerns a method for identifying and using a biomarker, or creating a proteome profile, indicative of a reduced response to a drug in a patient involving a thermal shift assay on a sample. The method comprises the steps of a) heating a sample from a patient b) separating soluble from insoluble protein, c) analysing either or both the soluble and insoluble protein fractions of step b) to determine the melting temperature.

Disclose herein is a portable platform based on a direct digital synthesizer (DDS) is investigated for the orthogonal SAW sensor, integrating signal synthesis, gain control, phase/amplitude measurement, and data processing in a small, portable electronic system. The disclosed platform allows for simultaneous removal of non-specific binding proteins, and mixing, as well as improved incubation time.

The invention features compositions and methods that are useful for increasing the level or activity of SLC16A11 in a subject, there by treating or preventing type 2 diabetes in the subject.

The present disclosure relates to a Mitochondria-Associated endoplasmic reticulum Membrane (MAM)-specific fluorescence calcium sensor and the use thereof. The present disclosure can surmount the limitations of a conventional technique in that verification of calcium migration through MAM requires separate measurements of calcium ion concentrations within ER and mitochondria and situational explanations of the phenomena, and can directly measure concentrations in the paths through which calcium ions move to exclude influences on calcium ion changes through numerous different calcium ion channels existing in mitochondria, thereby providing a convenient and accurate MAM-specific calcium ion sensor.